A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSciNeuro
About this trial
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
Eligibility criteria
Qualifiers
Confirmed diabetes mellitus Type 1 or Type 2, with stable glycemic control
Center-involved DME with CST >=320 µm (Study eye)
BCVA between 82 and 25 letters, inclusive (Study eye)
BCVA score ≥ 25 letters (Non-study eye)
Disqualifiers
None
Trial design
Treatments tested in this trial
- SNP318
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov